Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” on SHR-8925 for injectable use, and will conduct clinical trials in the near future.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” on SHR-8925 for injectable use, and will conduct clinical trials in the near future.